Media and Public Relations

Where Innovation Is Tradition

Media Sources Guide

Photo of Expert

Lance A. Liotta

University Professor and Co-director, Center for Applied Proteomics and Molecular Medicine

Web Site

Expertise: Health Care, Cancer, Nanotechnology, Bioengineering, Proteomics, Biomarkers

One of the first scientists to investigate the process of tumor invasion and metastasis at the molecular level, Liotta has invented technologies in the fields of diagnostics, immunoassays, microdissection, and proteomics that have been used to make broad discoveries in genomics, functional genetics, and tissue proteomics. Prior to joining George Mason University, he served as chief of the Laboratory of Pathology at the National Cancer Institute Center for Cancer Research and as deputy director for Intramural Research at the National Institutes of Health. Liotta earned a medical degree and a doctoral degree in biomedical engineering from Case Western Reserve University. His research contributions have generated 90 issued patents and more than 600 articles in peer-reviewed publications. Included among Liotta’s numerous awards for cancer research are three Public Health Service Commissioned Corps medals, the Arthur S. Fleming Award, the Warner Lambert/Parke Davis Award, the Rhoads Memorial Award, the Milken Family Foundation Award for Basic Research, the Lila Gruber Cancer Research Award, the U.S. Surgeon General’s Medallion, and the Maud L. Menten Lecture Award. In addition, he is the recipient of the National Institutes of Health Award of Merit, the Cotlove Research Award, the Ballantyne Distinguished Lectureship Research Award, and the Philip Levine Award for Outstanding Research.

Liotta and Center for Applied Proteomics and Molecular Medicine Co-director Emanuel F. Petricoin III, who are internationally recognized for their pioneering research in proteomics and molecular medicine, co-founded the George Mason University Center for Applied Proteomics and Molecular Medicine in 2005. They currently are exploring their recent discovery of an archive of protein fragments in the blood that are biomarker candidates for breast, ovarian, and lung cancers. Their immediate goals are to validate these potential biomarkers in clinical trials to determine their feasibility in the diagnosis of cancer prior to metastasis, and to analyze molecular pathways in diseased tissue to determine individualized and targeted treatments for patients. The team also is investigating the development and use of nanotechnology to synergize with proteomic tools for new types of biosensors, nanoparticles for biomarker discovery, and nanoelectronics. Liotta and Petricoin have more than 20 patents pending in the areas of cancer theranostics, biomarkers, and related technologies.

Media Contact: Michele McDonald, 703-993-8781,